about
The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?Assessment of Minimal Residual Disease in Standard-Risk AML.Differential association of cytoplasmic signalling molecules SHP-1, SHP-2, SHIP and phospholipase C-gamma1 with PECAM-1/CD31MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia.A novel role for PECAM-1 (CD31) in regulating haematopoietic progenitor cell compartmentalization between the peripheral blood and bone marrowExpression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia.Characterization of Siglec-5 (CD170) expression and functional activity of anti-Siglec-5 antibodies on human phagocytes.Siglec-5 (CD170) can mediate inhibitory signaling in the absence of immunoreceptor tyrosine-based inhibitory motif phosphorylation.Prognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia.Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid LeukemiaMYBL2 haploinsufficiency increases susceptibility to age-related haematopoietic neoplasia.Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage.A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.Assessment of minimal residual disease in acute myeloid leukemia.Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes.Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia.Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer.Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party.No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials.An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 low blasts.Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.T Cell Subset Enumeration and Weekend HIV Clinics: Reliable Performance of CD4 Cell Counts after 3 DaysContrasting requirements during disease evolution identify EZH2 as a therapeutic target in AMLIdentification of the CD33-related Siglec receptor, Siglec-5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemiasObesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancerDefining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 TrialProfessor David Grimwade (1962-2016)Induction response criteria in acute myeloid leukaemia: implications of a flow cytometric measurable residual disease negative test in refractory adultsApplicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre settingSerum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemiaMRD evaluation of AML in clinical practice: are we there yet?Molecular MRD status and outcome after transplantation in NPM1-mutated AML
P50
Q22009405-A60A9D43-CBAA-4C49-B1F3-6D39B3E41953Q27023660-AE51BDF0-9B59-4CF5-BE5B-250F970F34A5Q27853325-481A6F95-2BAD-473E-BDCC-7D56E50FE2F1Q28144872-3C77ED44-A50A-466E-BECA-CE07E3AC1507Q30412320-B5EFBD3E-A681-428B-BB55-E57116C8A39BQ33340245-5D6AE045-1164-4D12-B877-AC94D057A9E1Q33643108-BE0151F2-C026-4E17-9B74-24A1FFE52399Q34199349-F02E2B04-90C5-4F2F-B821-40848A456627Q34403249-5EDAE988-F712-4DE7-87B8-B8997636A910Q35348105-33786F7E-53C6-4E1C-8465-1578E09983E8Q36144842-8BA06F0D-F746-4F88-AC56-7BCC8E72EECEQ36670976-973D3DE1-F1C8-4528-B8F9-C30E7A866A4FQ37179007-75F7A3D4-DE65-4496-B2E1-DB55905FF71BQ37625632-A2AE0E74-9349-4A63-B6D5-4399A60949FFQ37784128-1AA921A9-3CBF-49A8-BC13-1D4E39CD9308Q42662727-B1F8A526-4CC8-4D9D-B585-2265FAA90A76Q45113941-8B87ED1A-DDAC-4157-9120-0441BD3C5A5CQ46319341-582E9C09-733B-4AA6-8C61-E2E9D69E8DD3Q46431139-7243A639-4BC1-4798-8C8B-3268FEA8BFE0Q47734674-ABDC2F92-624A-46DD-BF5B-2BE62290058CQ48139693-3424F65B-D09E-4F83-B23F-F4BC0089D082Q50566510-CD9CC9C2-6257-4CB7-86A1-AC7254AA18DAQ52619325-3C5B47F7-DA8A-4A94-9192-8750B38156F1Q56833732-614255B7-DA77-441D-9E89-82DC598F2CD5Q64076472-2BC50A87-9B88-4704-80EB-A94D7D562723Q79293581-A1ED0D45-2A04-4139-8B00-2A7C3DB5F77DQ79433843-90736195-4DDD-4763-A388-7D13EEB10C91Q86773433-6ABCB96B-62D3-4D85-A5E5-773C6CD30924Q89014463-3F68FF63-561F-4BCD-9B33-EDCFE283E039Q89942817-DAF287CC-9FE0-4ED7-837D-C9189CFFD685Q90296068-65F6310C-1323-4C27-8003-D4F5BDF1768FQ90841190-BB8A89C9-3315-4CDE-AF42-F6C7D7DE68D2Q90925312-34D49E20-BF6E-479F-B58D-29746B0AD83DQ91752560-5D96FB75-2BF4-4C95-9978-830A95BE3372Q92611548-7C2E22FD-CC69-4A4B-A93E-DFBC5759DF84
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
researcher
@en-gb
հետազոտող
@hy
name
Sylvie Freeman
@ast
Sylvie Freeman
@en
Sylvie Freeman
@en-gb
Sylvie Freeman
@es
Sylvie Freeman
@nl
Sylvie Freeman
@sl
type
label
Sylvie Freeman
@ast
Sylvie Freeman
@en
Sylvie Freeman
@en-gb
Sylvie Freeman
@es
Sylvie Freeman
@nl
Sylvie Freeman
@sl
prefLabel
Sylvie Freeman
@ast
Sylvie Freeman
@en
Sylvie Freeman
@en-gb
Sylvie Freeman
@es
Sylvie Freeman
@nl
Sylvie Freeman
@sl
P106
P21
P31
P496
0000-0003-1869-180X